Preclinical testing from a top preclinical Contract Research Organization in Kiev, Ukraine.
We are an independent CRO based in the U.S. that offers pre-clinical medicine toxicology in top-notch, Good Laboratory Practices certified testing facilities in Kiev, UA. Our testing laboratories are sponsored by the UNAMS and Ministry of Health and provide services for commercial development of new medicine discoveries as part of their core mission. The CRO was founded to provide the top-notch, inexpensive services of these facilities to start-up bio-tech companies in the United States and Europe, thereby offering a smart option for promoting development programs rapidly and at much lower cost than other commercial Contract Research Organizations. We provide a broad range of pre-clinical CRO including medicine safety, acute and chronic toxicity, pharma screening, bioavailability, bioequivalence, and complete in vivo and in vitro screening for anticancer activity.
Our preclinical Contract Research Organization is able to price preclinical research far below other CROs since we maintain a very low overhead in the USA and perform all research in Kiev where personnel and lab costs are much lower. Our team in the U.S. consists only of the company principals who deal directly with clients; we have no promotion costs aside from our website, and no main offices, administrative staff or other overhead to increase costs. We have much lower trials conduct costs in Kiev, UA due to much lower workers rates and are happy to provide our most attractive pricing for longer and more complex preclinical studies where labor is the most significant portion of the overall cost. Since we use the same reliable international suppliers for animal models, reagents and laboratory materials as other Contract Research Organizations, we have no cost advantage on these items and so less overall cost advantage for very short-term pre-clinical studies. However, regardless of your trial protocol and length, our goal is to provide our customers the best possible value for their investment.